254750-84-0

Upstream product

• 769-39-1 2,3,5,6-tetraflourophenol 
• 153088-76-7 (S)-3-benzyloxycarbonylamino-5-bromo-4-oxo-pentanoic acid tert-butyl ester 
• 118248-02-5 Z-Asp(OBut)-CHN₂ 
• 5545-52-8 Z-D(tBu)-OH 
• 254751-09-2 (S)-tert-butyl 3-(((benzyloxy)carbonyl)amino)-4-oxo-5-(2,3,5,6-tetrafluoro phenoxy)pentanoate 

Downstream Products

• 254751-10-5 (3S,4RS)-3-amino-5-(2',3',5',6'-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester 

Relevant academic research and scientific papers

CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF

Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases.

Caspase inhibitor and pharmaceutical composition, application and treatment method thereof

The invention provides a compound serving as a caspase inhibitor and particularly relates to a novel compound with caspase inhibition activity or a pharmaceutically acceptable salt of the novel compound, a preparation method of the novel compound and a ph

LINKED CYCLIC COMPOUND AS CASPASE INHIBITOR

A compound represented by formula (I), a pharmaceutically acceptable salt or tautomer thereof, and an application of the compound as a caspase inhibitor.

Structure-activity relationship study of a series of caspase inhibitors containing γ-amino acid moiety for treatment of cholestatic liver disease

A series of caspase inhibitors containing γ-amino acid moiety have been synthesized. A systemic study on their structure-activity relationship of anti-apoptotic cellular activity is presented. These efforts led to the discovery of compound 20o as a potent caspase inhibitor, which demonstrated preclinical ameliorating total bilirubin efficacy with a significantly improved pharmacokinetic profile.

CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD

The present invention relates to a pyridazinone derivative which can be used as a caspase inhibitor, process for the preparation thereof, and pharmaceutical composition for inhibiting caspase comprising the same.

CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD

The present invention relates to a pyridazinone derivative which can be used as a caspase inhibitor, process for the preparation thereof, and pharmaceutical composition for inhibiting caspase comprising the same.

CASPASE INHIBITORS CONTAINING DICARBONYLAMINO-ISOXAZOLINE

The present invention relates to a dicarbonylamino-isoxazoline derivative as an inhibitor against various caspases and a therapeutic composition for preventing inflammation and apoptosis comprising the same.

CASPASE INHIBITOR COMPRISING 2-ALKYL-4-OXOBUTANOYL GROUP AND PHARMACEUTICAL COMPOSITION THEREOF

The present invention relates to a compound of the formula (1), pharmaceutically acceptable salt, physiologically hydrolysable ester, hydrate, solvate, or steroisomer thereof having inhibitory activity against caspases. The compound contains unknown new 2

Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke

Structural modifications were made to a previously described acyl dipeptide caspase inhibitor, leading to the oxamyl dipeptide series. Subsequent SAR studies directed toward the warhead, P2, and P4 regions of this novel peptidomimetic are described herein.

ACTIVITY-BASED PROBES, AND METHODS OF THEIR PREPARATION AND USE

The present invention provides compositions and methods for assessing profiles of catalytically active enzymes in compositions containing a plurality of proteins. In preferred embodiments, the enzyme is a hydrolase, most preferably a cysteine protease. Th